Genzyme Articles
Positive CHMP recommendations for Astellas Xtandi, Roche's Erivedge, as well MACI, Nuedexta and Spedra
28 April 2013
Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed
25 March 2013
Makers of Kynamro and Fanaptum to appeal negative CHMP opinions
17 December 2012
FDA advisory gives thumbs down for Zogenix' Zohydro for chronic pain; EU label extension for Genzyme's Thyrogen
10 December 2012
Sanofi MS drug Aubagio gets second approval, in Australia
21 November 2012
News briefs from Genzyme, Sagent, Orchid and Kyowa Hakko
14 November 2012
Alnylam gets upfront $22.5 million in RNAi link with Genzyme
23 October 2012
FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro
19 October 2012
Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi
30 September 2012
FDA thumbs up for Sanofi's MS drug Aubagio
13 September 2012
Impax Labs settles with Genzyme over Renvela and Renagel generics
5 September 2012
FDA calls on Genzyme to re-file Lemtrada sBLA
28 August 2012
Sanofi moves on Lemtrada; Novartis Indian patent case
21 August 2012
Sanofi's strong 1st-qtr driven by Genzyme
27 April 2012
Genzyme and Isis file Kynamro NDA in USA
2 April 2012
GSK inks $300m rare diseases alliance with Angiochem
28 February 2012
Sanofi surprises Osiris by pulling out of Prochymal deal
13 February 2012
Positive Ph II results for Genzyme’s oral Gaucher drug
9 February 2012
Genzyme Framingham plant now cleared by US and EU regulators
24 January 2012
Isis sees Kynamro delay; adds new drugs to pipeline
15 December 2011
Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif
15 November 2011
Sanofi names David Meeker as chief executive of Genzyme; Exelixis hires former Genentech exec
25 October 2011
Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif
24 October 2011
Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing
21 October 2011
Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant
7 October 2011
Ongoing supply problems for Genzyme’s Cerezyme
19 September 2011
PTC Therapeutics and Genzyme restructuring ataluren collaboration
4 September 2011
Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv
1 September 2011
Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq
12 July 2011
Sanofi-Aventis net profit in 1st-qrt 2011 slumps 29%, battered by generics and low flu sales
29 April 2011
New president and CEO at Astellas Pharma Europe and in USA; Ex-Genzyme CEO joins AVEO board
13 April 2011
Merck & Co and Sanofi-Aventis drop plans to merge animal health operations; latter prices bond issue
23 March 2011
Strong Ph II data for Genzyme’s second Gaucher drug eliglustat
21 February 2011
Agreement on Sanofi-Aventis/Genzyme deal prompts lawyer comment on Europe/USA differences on takeovers
17 February 2011
Genzyme finally agrees takeover deal, as Sanofi-Aventis ups its offer to $74/share plus CVR
16 February 2011
Sanofi-Aventis net 4th-qtr 2010 falls, but still beats forecasts, as Genzyme talks progress
9 February 2011
Progress in Sanofi-Aventis bid to acquire Genzyme as it is allowed to conduct due diligence
1 February 2011
Novartis to acquire companion diagnostics maker Genoptix for around $470: Sanofi extends Genzyme offer
24 January 2011
Sanofi-Aventis gets EC approval for Genzyme bid; links with UCSF for early-stage research
13 January 2011
Genzyme posts record 4th-qtr 2010 revenues but cuts 2011 guidance, as Sanofi-Aventis talks continue
12 January 2011
Sanofi-Aventis confirms it is considering CVR-based deal regarding takeover of Genzyme
10 January 2011
Genzyme touts value of alemtuzumab for MS in bid to get Sanofi to raise its hostile offer
21 December 2010
Merck KGaA replaces Schnee; Sanofi-Aventis makes senior executive change and extends Genzyme tender offer
13 December 2010
US FTC challenges LabCorp's acquisition of rival clinical lab testing firm Westcliff
3 December 2010
Genzyme meets first milestones of FDA consent decree
25 November 2010
Genzyme hives off Diagnostics business to Japan’s Sekisui Chemical for $265 million; “white knight” expectations not certain
19 November 2010
Sanofi-Aventis tells takeover target Genzyme to clarify potential board actions; Genzyme sticks to its guns on value
9 November 2010
Sanofi-Aventis finds no reason to raise bid for Genzyme
28 October 2010
Genzyme argues case for higher valuation than Sanofi-Aventis ‘hostile offer, saying it is worth $89 a share
25 October 2010
Positive Ph II five-year results with Genzyme’s alemtuzumab in MS patients could prompt higher bid from Sanofi, observers suggest
18 October 2010
Genzyme board unanimously rejects Sanofi-Aventis’ $69/share tender offer as “inadequate and opportunistic”
8 October 2010
Sanofi-Aventis goes hostile with $69/share offer for Genzyme
4 October 2010
Sanofi may up bid for Genzyme, buys VaxDesign for $60m
28 September 2010
Japan approves Genzyme’s Synvisc for osteoarthritis of the knee and grants reimbursement
21 September 2010
Sanofi-Aventis CEO reasonably confident of doing deal for Genzyme, but in no hurry
16 September 2010
Genzyme snubs Sanofi-Aventis’ $18.5 billion offer; French drugmaker reports good data for MS drug teriflunomide
31 August 2010
Sanofi-Aventis breaks silence on Genzyme acquisition, offering $18.5 billion for the troubled US biotech firm
30 August 2010
Genentech and Seattle Genetics expand collaboration; Genzyme/Isis cholesterol candidate meets Ph III goals
5 August 2010
Sanofi-Aventis 2nd-qtr 2010 earnings up 8%, but firm still mute on Genzyme acquisition; sues over Lovenox
29 July 2010
Sanofi-Aventis debuts prostate cancer drug Jevtana in USA; Genzyme takeover still mooted
27 July 2010
Genzyme’s 2nd-qtr 2010 profits plunge on continuing Cerezyme and Fabrazyme supply problems
22 July 2010
Eight novel disease-modifying therapies will drive modest growth in the multiple sclerosis drug market through 2019
13 July 2010
US FDA approves GlaxoSmithKline’s Jalyn for symptomatic BPH; fast tracks Genzyme’s MS drug alemtuzumab
15 June 2010
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
